Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NICE updates methods in preparation for "widespread" use of biosimilars

This article was originally published in Scrip

Executive Summary

The National Institute for Health and Care Excellence (NICE) has reviewed and updated its methods for providing guidance and advice on biosimilars in preparation for an expected increase in the number of such products coming onto the market. Among other things it says biosimilars could be subject either to a technology appraisal (guidance) or to a less prescriptive "evidence summary".






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts